Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Ballow

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Advances in Therapy|June 7, 1995
Cost considerations in oral antibiotic therapyC H Ballow
The Annals of Pharmacotherapy|October 1, 1992
Azithromycin: the first azalide antibioticC H Ballow, G W Amsden
Diagnostic Microbiology and Infectious Disease|March 1, 1996
Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapyA D Kashuba, C H Ballow
Diagnostic Microbiology and Infectious Disease|February 1, 1992
Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance GroupC H Ballow, J J Schentag
Pharmacotherapy|September 1, 1996
Prospective validation of an optimal sparse plasma-sampling strategy for estimating ciprofloxacin pharmacokineticsG W Amsden, C H Ballow
The American Journal of Medicine|September 12, 1991
Tissue-directed pharmacokineticsJ J Schentag, C H Ballow
DICP : the Annals of Pharmacotherapy|April 1, 1991
Seizure activity associated with imipenem use: clinical case reports and review of the literatureR J Leo, C H Ballow
Current Opinion in Microbiology|October 26, 2000
New agents for Gram-positive bacteriaS M Bhavnani, C H Ballow
Antimicrobial Agents and Chemotherapy|August 1, 1996
Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidimeA D Kashuba, C H Ballow, A Forrest
Diagnostic Microbiology and Infectious Disease|July 13, 2001
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United StatesR N Jones, C H Ballow, D J Biedenbach, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Advances in Therapy|June 7, 1995
Cost considerations in oral antibiotic therapyC H Ballow
The Annals of Pharmacotherapy|October 1, 1992
Azithromycin: the first azalide antibioticC H Ballow, G W Amsden
Diagnostic Microbiology and Infectious Disease|March 1, 1996
Legionella urinary antigen testing: potential impact on diagnosis and antibiotic therapyA D Kashuba, C H Ballow
Diagnostic Microbiology and Infectious Disease|February 1, 1992
Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance GroupC H Ballow, J J Schentag
Pharmacotherapy|September 1, 1996
Prospective validation of an optimal sparse plasma-sampling strategy for estimating ciprofloxacin pharmacokineticsG W Amsden, C H Ballow
The American Journal of Medicine|September 12, 1991
Tissue-directed pharmacokineticsJ J Schentag, C H Ballow
DICP : the Annals of Pharmacotherapy|April 1, 1991
Seizure activity associated with imipenem use: clinical case reports and review of the literatureR J Leo, C H Ballow
Current Opinion in Microbiology|October 26, 2000
New agents for Gram-positive bacteriaS M Bhavnani, C H Ballow
Antimicrobial Agents and Chemotherapy|August 1, 1996
Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidimeA D Kashuba, C H Ballow, A Forrest
Diagnostic Microbiology and Infectious Disease|July 13, 2001
Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United StatesR N Jones, C H Ballow, D J Biedenbach, et al.
Pageof 3